Elekta and the Netherlands Cancer Institute have entered a collaboration to develop the next generation of radiation therapy solutions and introduce new treatments to patients.
Under the ten-year strategic partnership and research and development (R&D) alliance, the parties will expedite improvements in Elekta’s Unity and linac solutions by combining their expertise, resources and knowledge.
Improvements will be accelerated in solutions that include personalised and adaptive radiotherapy, imaging, new delivery approaches for cancer treatment, artificial intelligence, and software solutions for better workflow and decision support.
Elekta chief product officer Maurits Wolleswinkel said: “With this agreement, we will jointly further shape the future of radiation therapy through our research and product development relations.
“It demonstrates our commitment to partner-led innovation and to making the best cancer care accessible to everyone dealing with cancer.”
The Dutch comprehensive cancer centre will co-develop personalised treatment management software solutions and also transform its planning system to Elekta’s new treatment management solution.
Netherlands Cancer Institute medical physics radiotherapy head Anke van Mourik said: “The strength of this collaboration is the synergy in visions, the mutual innovative force and the close collaboration between research and the clinic.
“I am convinced that with our Elekta fleet and joint innovations, we can make a true impact on patient care.”
A founding member of Elekta’s MR-Linac Consortium, the Netherlands Cancer Institute will acquire a second Unity system as part of the agreement.
Separately, Elekta has announced the launch of a new radiosurgery system, Elekta Esprit, which will offer quick automated treatment planning and good visualisation for clinicians.
The system includes the next-generation Gamma Knife, which enables more personalised radiosurgery and offers remote access to clinicians.